Teleflex (NYSE:TFX) Given “Hold” Rating at Truist Financial

Teleflex (NYSE:TFX)‘s stock had its “hold” rating restated by equities research analysts at Truist Financial in a research report issued on Monday, Benzinga reports. They presently have a $227.00 price objective on the medical technology company’s stock, down from their prior price objective of $255.00. Truist Financial’s price objective would indicate a potential upside of 11.55% from the company’s previous close.

Other analysts have also issued research reports about the stock. Mizuho cut their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Stephens boosted their target price on shares of Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada lowered their target price on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $259.25.

Teleflex Stock Performance

Shares of TFX stock opened at $203.50 on Monday. The company’s fifty day simple moving average is $238.09 and its 200-day simple moving average is $224.11. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market cap of $9.45 billion, a PE ratio of 40.46, a P/E/G ratio of 1.92 and a beta of 1.18. Teleflex has a 12 month low of $195.51 and a 12 month high of $257.85.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. The business had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.64 earnings per share. Equities research analysts expect that Teleflex will post 13.97 EPS for the current fiscal year.

Insider Buying and Selling at Teleflex

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the transaction, the director now directly owns 5,496 shares in the company, valued at $1,313,159.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.43% of the company’s stock.

Hedge Funds Weigh In On Teleflex

Institutional investors and hedge funds have recently modified their holdings of the business. Cromwell Holdings LLC grew its stake in shares of Teleflex by 59.0% in the third quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 49 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Teleflex in the third quarter valued at about $40,000. GAMMA Investing LLC grew its stake in shares of Teleflex by 131.1% in the third quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after acquiring an additional 97 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Teleflex in the second quarter valued at about $42,000. Finally, Versant Capital Management Inc grew its stake in shares of Teleflex by 20,700.0% in the second quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 207 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.